Orexin

Tomoya Nakamachi*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

Orexin (also known as hypocretin) was discovered by reverse pharmacology as an endogenous ligand for two orphan G protein-coupled receptors in 1998. Orexin exists in two molecular forms, orexin-A and orexin-B, derived from the same 130-aa residue precursor (prepro-orexin). Orexin-A is a 33-aa residue peptide with two intrachain disulfide bonds that are fully conserved among tetrapods. Orexin-B is a linear 28-aa residue peptide. Orexin specifically binds to orexin receptors OX1R and OX2R. Orexin-A binds to OX1R and OX2R with a high affinity, whereas orexin-B selectively binds to OX2R with a similar high affinity. Orexin systems have roles in regulating feeding and drinking behavior, metabolism, the sleep-wake cycle, and the endocrine system.

Original languageEnglish
Title of host publicationHandbook of Hormones
Subtitle of host publicationComparative Endocrinology for Basic and Clinical Research
PublisherElsevier
Pages133-135
Number of pages3
ISBN (Electronic)9780128206492
DOIs
StatePublished - 2021/01/01

Keywords

  • Appetite
  • GPCR
  • Hypocretin
  • Metabolism
  • Narcolepsy
  • OX1R
  • OX2R
  • Sleep-wake cycle

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Orexin'. Together they form a unique fingerprint.

Cite this